Kanghong Pharmaceutical: Cancellation of the "Kanghong Pharmaceutical Solid Oral Dosage Form Improving and Expanding Project" Fund-raising Account.

Kanghong Pharmaceutical announced that the actual net proceeds from the company's initial public offering of shares was 576 million yuan, and the actual net proceeds from the public offering of convertible bonds was 1.609 billion yuan, both managed in special accounts. As the "Kanghong Pharmaceutical Solid Oral Dosage Form Project" in another location has been completed, the company transferred the remaining balance of 1.1331 million yuan from the project fundraising special account to the basic account on December 23, 2025, to permanently supplement working capital. The closure procedures were completed, and the remaining final payment/retention money for the project will be paid using the company's own funds, with the relevant regulatory agreements terminated accordingly.